PharmaEssentia Valuation

Q: What is the Fair Price of 261280523 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

261280523 ($17.4) is trading below our estimate of [[fair value]] ($41.64)

Is 261280523 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 261280523 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 261280523 ($17.4) is trading below our estimate of fair value ($41.64)

Significantly Below Fair Value: 261280523 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 261280523?

Key metric: As 261280523 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 261280523. This is calculated by dividing 261280523's market cap by their current earnings.
What is 261280523's PE Ratio?
PE Ratio	102.1x
Earnings	NT$1.85b
Market Cap	NT$188.41b

261280523 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	20.3x
Enterprise Value/EBITDA	143.9x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does 261280523's PE Ratio compare to its peers?

The above table shows the PE ratio for 261280523 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	64.6x
ADMA ADMA Biologics	75.7x	30.5%	US$5.2b
AGIO Agios Pharmaceuticals	5x	-56.7%	US$3.4b
TLX Telix Pharmaceuticals	161.8x	38.3%	AU$7.8b
HALO Halozyme Therapeutics	15.7x	21.1%	US$6.1b
261280523 PharmaEssentia	102.1x	92.0%	US$188.4b

Price-To-Earnings vs Peers: 261280523 is expensive based on its Price-To-Earnings Ratio (102.1x) compared to the peer average (63.8x).

Price to Earnings Ratio vs Industry

How does 261280523's PE Ratio compare vs other companies in the European Biotechs Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 261280523 is expensive based on its Price-To-Earnings Ratio (102.1x) compared to the European Biotechs industry average (26.5x).

Price to Earnings Ratio vs Fair Ratio

What is 261280523's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

261280523 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	102.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 261280523's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.